Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Albireo Pharma, Inc. (ALBO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
26.03-0.14 (-0.53%)
At close: 04:00PM EST
26.03 0.00 (0.00%)
After hours: 04:10PM EST
Advertisement

Albireo Pharma, Inc.

10 Post Office Square
Suite 1000
Boston, MA 02109
United States
857 254 5555
https://www.albireopharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees90

Key Executives

NameTitlePayExercisedYear Born
Mr. Ronald H. W. CooperCEO, Pres & Director1.13MN/A1963
Ms. Martha J. CarterChief Regulatory Officer745.73kN/A1952
Dr. Per-Goran GillbergCo-Founder & VP of Devel.N/AN/AN/A
Dr. Jan P. Mattsson Ph.D.Chief Scientific Officer, MD (Sweden) & Co-FounderN/AN/A1964
Mr. Simon Nicolas Reade HarfordCFO & TreasurerN/AN/A1962
Ms. Joan ConnollyChief Technology OfficerN/AN/AN/A
Mr. Jason G. DuncanChief Legal Officer, Gen. Counsel & Sec.N/AN/A1975
Ms. Michelle GrahamChief HR OfficerN/AN/A1967
Dr. Kristina TorfgardVP & Global Project HeadN/AN/AN/A
Ms. Pamela Stephenson M.P.H.Chief Commercial OfficerN/AN/A1968
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis. It has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. The company is headquartered in Boston, Massachusetts.

Corporate Governance

Albireo Pharma, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 7. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement